tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Demetris AJ et al. Pathologic observations in human allograft recipients treated with FK 506. 1990 Transplant. Proc. pmid:1689891
Kumar MS et al. ATGAM versus OKT3 induction therapy in cadaveric kidney transplantation: patient and graft survival, CD3 subset, infection, and cost analysis. 1998 Transplant. Proc. pmid:9636549
Asselin I et al. Polymerase chain reaction-based assay to assess the success of myoblast transplantation in mdx mice. 1994 Transplant. Proc. pmid:7527970
Kinoshita I et al. Immunosuppression with FK 506 insures good success of myoblast transplantation in MDX mice. 1994 Transplant. Proc. pmid:7527978
Diez Ojea B et al. Three-month experience with tacrolimus once-daily regimen in stable renal allografts. 2009 Jul-Aug Transplant. Proc. pmid:19715908
Azhderian EM et al. Nucleus associated FK 506 binding proteins with potential relevance to FK 506 immunosuppression. 1993 Transplant. Proc. pmid:7679834
Corry RJ et al. Tacrolimus without antilymphocyte induction therapy prevents pancreas loss from rejection in 123 consecutive patients. 1998 Transplant. Proc. pmid:9532157
Dheir H et al. Intensive polyoma virus nephropathy treatment as a preferable approach for graft surveillance. 2011 Transplant. Proc. pmid:21486617
Waller JR et al. Mycophenolate mofetil inhibits intimal hyperplasia and attenuates the expression of genes favouring smooth muscle cell proliferation and migration. 2005 Jan-Feb Transplant. Proc. pmid:15808582
Porayko MK et al. Nephrotoxicity of FK 506 and cyclosporine when used as primary immunosuppression in liver transplant recipients. 1993 Transplant. Proc. pmid:7679835
Cimsit B et al. Successful treatment of fibrosing cholestatic hepatitis after liver transplantation. 2011 Transplant. Proc. pmid:21486625
Zhao Y et al. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus. 2005 Jan-Feb Transplant. Proc. pmid:15808586
Kawauchi M et al. Plasma level of FK 506 in newborn goats and infant baboons. 1991 Transplant. Proc. pmid:1721267
Iwasaki K et al. Pharmacokinetic study of FK 506 in the rat. 1991 Transplant. Proc. pmid:1721268
Andersson J et al. FK 506 and cyclosporine inhibit antigen- or mitogen-induced monokine and lymphokine production in vitro. 1992 Transplant. Proc. pmid:1371621
Morozumi K et al. A comparative study of morphological characteristics of renal injuries of tacrolimus (FK506) and cyclosporin (CyA) in renal allografts: are the morphologic characteristics of FK506 and CyA nephrotoxicity similar? 1996 Transplant. Proc. pmid:8623232
Takada S et al. HGF prevents tacrolimus (FK 506)-induced nephrotoxicity in SHR rats. 1996 Transplant. Proc. pmid:8623236
Shimada H et al. Existence of serum p53 antibodies in cyclosporine A-treated transplant patients: possible detection of p53 protein over-expression. 2000 Transplant. Proc. pmid:11119931
Vela CG et al. Prospective study of lipid disorders in FK506-versus cyclosporine-treated renal transplant patients. 2000 Transplant. Proc. pmid:10715453
Kim HC and Park SB Mycophenolate mofetil-induced ischemic colitis. 2000 Transplant. Proc. pmid:11119990
Land W et al. Mycophenolate mofetil monotherapy: an optimal, safe, and efficacious immunosuppressive maintenance regimen in kidney transplant patients. 2001 Transplant. Proc. pmid:11406265
Díaz-Molina B et al. Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation. 2012 Transplant. Proc. pmid:23146479
Maggard M et al. Incidence of acute rejection in African-American liver transplant recipients. 1998 Transplant. Proc. pmid:9636607
Watarai Y et al. Effect of tacrolimus and cyclosporine on renal microcirculation and nitric oxide production. 2004 Transplant. Proc. pmid:15518773
Furlan V et al. Interaction between tacrolimus and itraconazole in a heart-lung transplant recipient. 1998 Transplant. Proc. pmid:9474996
Birk PE et al. Preliminary experience with FK 506 in pediatric renal transplant recipients: a single-center report. 1996 Transplant. Proc. pmid:8623493
Nelson PA et al. Effect of immunosuppressive drugs on cytokine gene transcription studied by message amplification phenotyping (MAPPing) polymerase chain reaction. 1991 Transplant. Proc. pmid:1721299
Ishibashi M et al. Elimination of the adverse effects of tacrolimus-based induction therapy by a 5-day exposure of optimal steady-state blood concentration in renal transplant patients in the early postoperative period. 1999 Transplant. Proc. pmid:10578281
Telkes G et al. Kidney transplantation in hereditary coproporphyria using tacrolimus and mycophenolate mofetil: a case report. 2013 Transplant. Proc. pmid:24315002
González-Pinto IM et al. Five-year follow-up of a trial comparing Tacrolimus and cyclosporine microemulsion in liver transplantation. 2005 Transplant. Proc. pmid:15919441
Nakamura Y et al. Evaluation of appropriate blood level in continuous intravenous infusion from trough concentrations after oral administration based on area under trough level in tacrolimus and cyclosporine therapy. 2005 Transplant. Proc. pmid:15919445
Jain A et al. FK 506 in small bowel transplant recipients: pharmacokinetics and dosing. 1994 Transplant. Proc. pmid:7518149
Takara T et al. Intraportal donor-specific transfusion given 24 hours before small bowel transplantation with cyclosporine and FK 506. 1994 Transplant. Proc. pmid:7518150
Furukawa H and Todo S Evolution of immunosuppression in liver transplantation: contribution of cyclosporine. 2004 Transplant. Proc. pmid:15041353
Hatazawa C et al. Effect of FK 506 on bowel transplantation in rats. 1992 Transplant. Proc. pmid:1376517
Zeevi A et al. Serial evaluation of immune profiles of simultaneous bone marrow and whole organ transplant recipients. 1995 Transplant. Proc. pmid:7533388
Watanabe K et al. Factors influencing long-term operational tolerance in dogs treated with fractionated lymphoid irradiation, donor bone marrow cell infusion and FK506. 1995 Transplant. Proc. pmid:7533389
Kawauchi M et al. Flow cytometric analysis of lymphocyte populations in FK 506-treated newborn goats. 1991 Transplant. Proc. pmid:1721331
Ishikawa T et al. Intestinal function and morphology after ex vivo irradiated small bowel transplantation. 2002 Transplant. Proc. pmid:12034274
Charco R et al. Changes in renal function in long-term survivors of liver transplantation: a comparison between cyclosporine microemulsion and tacrolimus therapy. 2002 Transplant. Proc. pmid:12176478
Dierickx D et al. Thrombotic microangiopathy following intestinal transplantation: a single center experience. 2010 Jan-Feb Transplant. Proc. pmid:20172285
Yokoyama I et al. Immunosuppressant effect on Fas antigen expression and p53 of an experimental tumor. 1998 Transplant. Proc. pmid:9865346
Prasad GV et al. Role of dietary salt intake in posttransplant hypertension with tacrolimus-based immunosuppression. 2005 Transplant. Proc. pmid:15919496
Kobayashi M et al. Posttransplant donor-specific T-lymphocytotoxic antibody in liver transplant patients with a positive crossmatch. 1992 Transplant. Proc. pmid:1281570
Japanese study of FK 506 on kidney transplantation: results of an early phase II study. Japanese FK 506 Study Group. 1991 Transplant. Proc. pmid:1721363
Miller J et al. FK 506 in kidney transplantation: results of the U.S.A. randomized comparative phase III study. The FK 506 Kidney Transplant Study Group. 1997 Feb-Mar Transplant. Proc. pmid:9123008
van Hoek B et al. Recurrence of ductopenic rejection in liver allografts after retransplantation for vanishing bile duct syndrome. 1991 Transplant. Proc. pmid:1703343
Jensen CW et al. Pediatric renal transplantation under FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721364
McCauley J et al. The question of FK 506 nephrotoxicity after liver transplantation. 1991 Transplant. Proc. pmid:1703344
Toyama Y et al. Prolonged small bowel graft survival using photochemotherapy and low-dose FK 506. 1996 Transplant. Proc. pmid:8907924
Malaise J et al. Tacrolimus compared with cyclosporine microemulsion in primary simultaneous pancreas-kidney transplantation: the EURO-SPK 3-year results. 2005 Jul-Aug Transplant. Proc. pmid:16182828
Malaise J et al. Corticosteroid withdrawal in simultaneous pancreas-kidney transplantation: a 3-year report. 2005 Jul-Aug Transplant. Proc. pmid:16182832
Crespo-Leiro MG Tacrolimus in heart transplantation. 2003 Transplant. Proc. pmid:12962869
Espí A et al. Influence of hepatic ischemia-reperfusion injury on tacrolimus acute renal toxicity in pigs. 2002 Transplant. Proc. pmid:12493373
Aumente Rubio MD et al. Clinical pharmacokinetics of tacrolimus in heart transplantation: new strategies of monitoring. 2003 Transplant. Proc. pmid:12962871
Soylu H et al. Survival of renal transplant patients: data from a tertiary care center in Turkey. 2015 Transplant. Proc. pmid:25769571
Dietl KH Oral dosing of tacrolimus and cyclosporine microemulsion--results from a large multicenter study in renal transplantation. 2002 Transplant. Proc. pmid:12176524
Karakulska-Prystupiuk E et al. Pericarditis in Patients With Chronic Graft-vs-Host Disease. 2018 Transplant. Proc. pmid:30177139
Gurkan A et al. Comparison of tacrolimus and neoral-based immunosuppressive regimens in renal transplantation patients: singles-center experience. 2002 Transplant. Proc. pmid:12176525
Humar A et al. Surgical complications requiring early relaparotomy after pancreas transplantation: comparison of the cyclosporine and FK 506 eras. 1999 Feb-Mar Transplant. Proc. pmid:10083256
Shapiro R et al. Reversibility of tacrolimus-induced posttransplant diabetes: an illustrative case and review of the literature. 1997 Transplant. Proc. pmid:9290809
Tsuchiya T et al. Effect of conversion from twice-daily to once-daily tacrolimus on glucose intolerance in stable kidney transplant recipients. 2012 Transplant. Proc. pmid:22310593
Kumano K et al. Role of the transforming growth factor and monocyte chemoattractant protein in FK506-induced nephropathy in the rat. 1997 Feb-Mar Transplant. Proc. pmid:9123293
Gudas VM et al. Comparison of the immunosuppressive and toxic effects of FK506 and cyclosporine in xenograft recipients. 1989 Transplant. Proc. pmid:2468211
Carroll PB et al. FK 506-associated diabetes mellitus in the pediatric transplant population is a rare complication. 1991 Transplant. Proc. pmid:1721396
Grochowicz PM et al. Synergistic interaction between castanospermine and tacrolimus in a rat heart allograft model. 1997 Feb-Mar Transplant. Proc. pmid:9123296
Wilczek HE et al. Renal transplant histopathologic changes during the first year in patients with tacrolimus (FK 506). 1996 Transplant. Proc. pmid:8962232
Yussim A et al. Conversion from cyclosporine to tacrolimus in hepatic and renal transplantation. 1996 Transplant. Proc. pmid:8962233
Wierzbicka A et al. Lipid, carbohydrate metabolism, and antioxidant status in children after liver transplantation. 2007 Transplant. Proc. pmid:17580179
Nakache R et al. Management of massive proteinuria following renal transplantation with mycophenolate mofetil and blood pressure normalization. 2001 Transplant. Proc. pmid:11377533
Baran DA et al. A novel tacrolimus dosing strategy in cardiac transplantation: drug levels, renal function, and biopsy results. 2002 Transplant. Proc. pmid:12176595
Ettenger R The practical problems of prednisone in pediatric renal transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267159
Sánchez Pérez B et al. Adverse effects on the lipid profile of immunosuppressive regimens: tacrolimus versus cyclosporin measured using C2 levels. 2009 Transplant. Proc. pmid:19376418
Reggiani P et al. Reduced acute rejection after liver transplantation with Neoral-based double immunosuppression. 1998 Transplant. Proc. pmid:9723308
Testillano M et al. Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: experience in a single center. 2009 Transplant. Proc. pmid:19376421
Takeda Y et al. Effect of FK 506 on the survival of rat small bowel allografts. 1991 Transplant. Proc. pmid:1721426
Kokado Y et al. Hypertension in renal transplant recipients and its effect on long-term renal allograft survival. 1996 Transplant. Proc. pmid:8658802
Fukuzawa M et al. Effect of donor-specific transfusion and FK 506 on small intestine allotransplantation. 1991 Transplant. Proc. pmid:1721427
Park KM et al. Bone loss after orthotopic liver transplantation: FK 506 versus cyclosporine. 1996 Transplant. Proc. pmid:8658863
Kishikawa H et al. Low-dose steroid maintenance for renal transplant recipients. 2010 Transplant. Proc. pmid:21168618
Tamura K et al. A highly sensitive method to assay FK-506 levels in plasma. 1987 Transplant. Proc. pmid:2445069
Tinti F et al. Improvement of graft function after conversion to once daily tacrolimus of stable kidney transplant patients. 2010 Transplant. Proc. pmid:21168623
Venkataramanan R et al. Biopharmaceutical aspects of FK-506. 1987 Transplant. Proc. pmid:2445070
Ji SM et al. Rescue therapy by immunoadsorption in combination with tacrolimus and mycophenolate mofetil for C4d-positive acute humoral renal allograft rejection. 2006 Transplant. Proc. pmid:17175303
Shaffer D et al. Calcineurin inhibitor avoidance versus steroid avoidance following kidney transplantation: Postoperative complications. 2006 Transplant. Proc. pmid:17175304
López-Vilella R et al. Incidence of development of obesity after heart transplantation according to the calcineurin inhibitor. Transplant. Proc. pmid:25645789
Mueller AR et al. Influence of immunosuppression on patient survival after liver transplantation for hepatitis C. 2001 Feb-Mar Transplant. Proc. pmid:11267321
Cofan F et al. Fatty acid composition in low-density lipoproteins from renal transplant recipients. 1999 Transplant. Proc. pmid:10500603
Kattner A et al. Conversion from CyA to CyA-NOF in a cholestatic liver grafted patient with CyA malabsorption. 1994 Transplant. Proc. pmid:7524225
Abou-Jaoude MM et al. Tacrolimus (FK506) versus cyclosporine microemulsion (neoral) as maintenance immunosuppression therapy in kidney transplant recipients. 2005 Transplant. Proc. pmid:16213293
Carroll PB et al. The use of FK 506 in new-onset type I diabetes in man. 1991 Transplant. Proc. pmid:1721458
Wakabayashi H et al. Effect of FK 506 and cyclosporine A on hepatic energy status in the rat after warm ischemia, as monitored by 31P nuclear magnetic resonance spectroscopy in vivo. 1992 Transplant. Proc. pmid:1384205
Mita A et al. Optimal initial dose of orally administered once-daily extended-release tacrolimus following intravenous tacrolimus therapy after liver transplantation. 2014 Transplant. Proc. pmid:24767351
Braun F et al. Primary low-dose tacrolimus immunosuppressive prophylaxis for high-risk kidney transplant recipients. 1998 Transplant. Proc. pmid:9636496
Tanabe K et al. Long-term results of living kidney transplantation under tacrolimus immunosuppression: a single-center experience. 1998 Transplant. Proc. pmid:9636497
Mehra MR et al. Corticosteroid weaning in the tacrolimus and mycophenolate era in heart transplantation: clinical and neurohormonal benefits. 2004 Transplant. Proc. pmid:15686716
Hildebrandt A et al. FK 506: short- and long-term treatment after cardiac transplantation in nonhuman primates. 1991 Transplant. Proc. pmid:1703694
Dallos G et al. Results and complications after living related kidney transplantation in Hungary: 30 years' experience. 2010 Jul-Aug Transplant. Proc. pmid:20692470
Williams ST et al. Preliminary analysis of a randomized trial comparing microemulsion cyclosporine and tacrolimus for recipients of renal transplants from non-heart-beating donors. 2000 Transplant. Proc. pmid:10701022
Boggi U et al. Single-center, open, prospective, randomized pilot study comparing cyclosporine versus tacrolimus in simultaneous pancreas-kidney transplantation. 2004 Transplant. Proc. pmid:15194369